Skip to Main Content

Paper Details

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy.
Nat Commun
18
2023
CAR, CAR T cell, CAR) T cell, CBD, IL-12, PSMA, STEAP1, STEAP1 CAR T cell, STEAP1 CAR T cells, STEAP1 chimeric antigen receptor, STEAP1 chimeric antigen receptor T cell, Six transmembrane epithelial antigen of the prostate 1, advanced prostate cancer, chimeric, chimeric antigen receptor, collagen binding domain, human, interleukin-12, metastatic prostate cancer, metastatic prostate cancers, mouse, prostate cancer, prostate-specific membrane antigen, tumor
Author NameAffiliation
Ilsa ColemanFred Hutchinson Cancer Center
Lawrence D TrueUniversity of Washington
Colm MorrisseyUniversity of Washington
Michael C HaffnerFred Hutchinson Cancer Center
Michael C HaffnerUniversity of Washington
Michael C HaffnerClinical Research Division, Fred Hutchinson Cancer Center
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington
Peter S NelsonUniversity of Washington
Peter S NelsonClinical Research Division, Fred Hutchinson Cancer Center
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Center
Peter S NelsonUniversity of Washington
Peter S NelsonUniversity of Washington
Peter S NelsonClinical Research Division, Fred Hutchinson Cancer Center
  • 1 - 18

Datasets

Release 1.2